Outlook Therapeutics Inc (OTLK)

[H2R]

Hi VMLG17,

What I'm reading from it is the price pressure to remain competitive.

1. "Meanwhile, insurers — primarily Medicare in the U.S. — have been looking to reduce the costs of paying for physician services."

2. "Vabysmo [...] $2,190 a shot, is competitive with Lucentis biosimilars, which cost around $1,000 a shot."

From memory, OTLK is targeting a price structure under $1,000, and above the current compound pharmacies. In other words, in a sweet spot which will make it attractive to payers and quite competitive against the established players.

And since it's positioned to replace the need to use unapproved repackaged IV bevacizumab, which is fairly widely used today, it's not going to be a big step to move there.

All in all, the price pressure makes sense and OTLK can carve a nice place in this market.

My 2 cents.

Best of luck with your investments!